In vitro and in vivo studies revealed that inhibiting miR-181b expression alleviated hepatic steatosis, while overexpressing SIRT1 blocked the pathological effects of miR-181b, suggesting that targeting miR-181b could be a therapeutic strategy for MASLD [65]. Here, SIRT1 is linked to fatty liver disease.